GLP-1 receptor agonists were initially developed and approved for glycemic control in patients with type 2 diabetes mellitus and subsequently demonstrated efficacy in weight reduction [32] and cardiovascular risk reduction. Here, GLP1R is linked to type 2 diabetes mellitus.